In new, yet unpublished data from a project by Joslyn Kirby, Ashley Eichelberger, Melissa Butt, Colleen Silva, and Aretha Mosley of Penn State Hershey School of Medicine, patients shared their thoughts and experience about long-distance dermatology visits.
Hidradenitis suppurativa (HS) is a condition caused by an over-active immune system and many of the treatments influence the immune system. At the start of the COVID pandemic, many people were taking medicines, like injected shots, for HS, psoriasis or other conditions. In the beginning there weren’t a lot of studies showing the benefits and risks of the treatments. In a new study led by Dr. Rebecca Haberman of New York University and published April 2020 in the New England Journal of Medicine, a group of doctors studied whether people being treated for immune diseases had more severe COVID.
Giving infliximab the best chance of working for Hidradenitis Suppurativa (HS) from the start means getting the dose right. In a retrospective study led by Dr. Christopher Sayed of University of North Carolina and published September 2019 in the Journal of the Academy of Dermatology, the authors investigated the variety of ways infliximab was used to treat people with HS.
International HS experts have recently established the Global HS COVID-19 Registry to better understand the risk of infection and clinical course, track outcomes, and inform treatments of pediatric and adult HS patients in the setting of COVID-19. HS clinicians worldwide are encouraged to report ALL cases of COVID-19 in HS patients, regardless of severity – including asymptomatic patients detected through public health screenings.
Patients may also contribute to the Registry.
Information about the Registry as well as a link to report cases can be found at http://hscovid.ucsf.edu.
The success of this global collaborative effort depends on active participation by providers who care for HS patients, so broad sharing of the registry with colleagues treating HS patients is encouraged.
An early study for a new injectable treatment shows improvement in Hidradenitis Suppurativa (HS) activity and pain scores while demonstrating safety. Dr. Alice Gottlieb of Icahn School of Medicine at Mount Sinai, New York led the research investigating the results of bermekimab use in 42 patients with Hidradenitis Suppurativa. The results were recently published in the Journal of Investigative Dermatology.
Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa
New findings, recently published in JAMA Dermatology, appear to show that having HS confers a modest risk of having a heart attack or a stroke. Patients should discuss with their doctors strategies to reduce this risk, including smoking cessation and good control of blood sugar, blood pressure and cholesterol levels.
To view the article, click here.